Institutional Cluster

BBIO

BridgeBio Pharma, Inc.
MIXED
Impact 6/10
Horizonmonths Processed1mo ago
Institutional cluster: 33 buyers, 25 sellers (mixed)
Actionable Insight ◆ Mixed

The active-quant buying cluster (D.E. Shaw, Jane Street, RenTech, Point72, Bridgewater) is a strong signal that sophisticated investors are positioning for the upcoming PDUFA catalysts (BBP-418 Nov 2026, encaleret May 2027). The passive selling is likely index-rebalancing noise. Monitor for any insider buying to corroborate the thesis — current insider activity shows 7 sells in the last 30 days with no open-market buys, which is a divergence. The $1B preferred equity financing provides a cash runway through these catalysts.

DirectionMixed
Confidencemedium
Horizonmonths
Latest settled — T+20d
BBIO ▼ -14.60% at T+20d
NEUTRAL call ✗ call lost -14.60% · α vs SPY -15.92% · entry $81.07 → $69.23
Next anchor: T+60d in 6w
Latest observation: T+27 -29.12% FF3 residual α
Entry anchored
Aug 21, 04:00 PM ET
via 1-min bar
T+1d
-0.83%
call -0.83% · α -1.15%
$80.40
settled 6w ago
T+5d
-5.53%
call -5.53% · α -6.00%
$76.59
settled 5w ago
T+20d
-14.60%
call -14.60% · α -15.92%
$69.23
settled 11d ago
T+60d
—
call — · α —
—
in 6w

Executive Summary

BridgeBio Pharma saw a mixed institutional cluster in Q2 2026, with 33 buyers adding $561.6M in net new positions (led by Norges Bank, Point72, and D.E. Shaw) while 25 sellers trimmed $218.2M (led by Geode and Northern Trust). The buying is concentrated among active quant and asset managers (D.E. Shaw, Jane Street, RenTech, Point72) likely positioning ahead of key PDUFA catalysts (BBP-418 Nov 2026, encaleret May 2027) and the $1B preferred equity financing, while the selling is dominated by mega-passive index funds (Geode, T. Rowe Price) trimming for rebalancing. The divergence between active buyers and passive sellers, combined with the strong Q2 revenue growth ($243.7M, more than doubling YoY) and the recent $1B capital raise, suggests conviction in the pipeline catalysts outweighs the EPS miss and ongoing operating losses.

Key Financial Metrics

Direction
mixed
Buy Value
$1.1B
Net Flow
$343.4M

Institutional Positions

Net institutional flow: $343.4M

▲ Buyers (33)

InstitutionActionChangePosition ValueValue Δ
Norges BankNEW+100%$126.2M$126.2M
Point72NEW+100%$113.6M$113.6M
D.E. ShawADD+42.7%$270.6M$81.6M
Jane Street GroupADD+66.9%$218.5M$88.0M
RenTechDOUBLED+134.3%$63.8M$36.7M

▼ Sellers (25)

InstitutionActionChangePrev ValueValue Δ
GeodeTRIM-30.5%$371.9M-$117.3M
Northern TrustTRIM-31.6%$104.2M-$32.8M
American Century CompaniesTRIM-43%$81.0M-$34.7M
Walleye CapitalNEAR_EXIT-99.3%$17.0M-$16.9M
T. Rowe PriceTRIM-54.6%$282.0K-$153.7K

Key Facts

  • 33 institutional buyers added $561.6M in net new positions in Q2 2026
  • 25 institutional sellers trimmed $218.2M, led by mega-passive index funds
  • Norges Bank initiated a new $126.2M position; Point72 initiated $113.6M
  • D.E. Shaw added $81.6M (+42.7%), Jane Street added $88.0M (+66.9%)
  • Geode trimmed $117.3M (-30.5%), Northern Trust trimmed $32.8M (-31.6%)
  • Q2 2026 revenue $243.7M (more than doubled YoY) but EPS missed consensus ($0.78 actual vs $0.64 consensus)
  • Key catalysts: BBP-418 PDUFA Nov 27, 2026; encaleret PDUFA May 8, 2027
  • $1B preferred equity financing completed post-quarter

Financial Impact

Net institutional buying of $561.6M by 33 buyers vs $218.2M selling by 25 sellers, for a net inflow of approximately $343.4M in Q2 2026

institutional ownershipfloatvaluation

Risk Factors

  • EPS miss of $0.78 vs $0.64 consensus indicates ongoing profitability challenges
  • No insider open-market buying to corroborate the institutional thesis
  • PDUFA catalysts are binary events with significant downside risk on failure
  • 13F data is 45+ days stale; positions may have been adjusted since quarter-end

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-BBIO-2026-Q2
26 reports for BBIO
Performance horizon
90% Hit rate 9 of 10 directional calls best @ T+60▲ +26.76%May 11, 2026
Filters
Rows
Reports for BBIO — sortable, filterable
TypeNow
Aug 31, 2026
4w ago
8-K
NEUTRAL ★ 4/10
$76.59 $65.97▼ −13.87%▼ −13.68%—
Aug 26, 2026
5w ago
Press Release
BULLISH ★ 7/10
$79.37 $66.28▼ −16.49%▼ −16.72%—
Aug 22, 2026
5w ago
Institutional Cluster
MIXED ★ 6/10
$81.07 $69.23▼ −14.60%▼ −15.92%—
Aug 17, 2026
6w ago
8-K
NEUTRAL ★ 4/10
$79.89 $72.38▼ −9.40%▼ −7.87%—
Aug 13, 2026
7w ago
Press Release
BEARISH ★ 5/10
$79.86 $72.38▲ +9.37%▲ +7.38%—
Aug 10, 2026
7w ago
8-K
NEUTRAL ★ 5/10
$84.67 $76.08▼ −10.15%▼ −9.09%—
Aug 10, 2026
7w ago
Press Release
MIXED ★ 6/10
$84.67 $76.08▼ −10.15%▼ −9.09%—
Jul 13, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$83.08 $84.67▲ +1.91%▼ −1.27%—
Jun 28, 2026
13w ago
Press Release
BULLISH ★ 8/10
$72.01 $84.02▲ +16.68%▲ +16.96%—
Jun 24, 2026
14w ago
144
NEUTRAL ★ 2/10
$69.69 $82.93▲ +19.00%▲ +18.47%—
Showing 10 of 26

US Market Status

Market Open — Closes in 2h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 22, 2026